Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00460408
First received: April 13, 2007
Last updated: November 14, 2012
Last verified: November 2012
  Purpose

The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.


Condition Intervention
Macular Degeneration
Drug: Macugen

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased intraocular pressure (IOP), vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection equals (=) number of specific POAEs divided by the total number of injections received.

  • Incidence of POAEs Per Injection Reported by Gender (Females) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.


Secondary Outcome Measures:
  • Incidence of POAEs Per Injection Reported by Gender (Males) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.

  • Incidence of POAEs Per Injection Reported by Age Group (≤ 50 Years) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.

  • Incidence of POAEs Per Injection Reported by Age Group (51 to 64 Years) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.

  • Incidence of POAEs Per Injection Reported by Age Group (65 to 74 Years) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.

  • Incidence of POAEs Per Injection Reported by Age Group (≥ 75 Years) [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    POAEs: primarily endophthalmitis, as well as increased IOP, vitreous hemorrhage, traumatic cataract, retinal detachment, and retinal tear. Incidence of POAEs per injection = number of specific POAEs divided by the total number of injections received.

  • Number of Participants With Serious Hypersensitivity Reactions [ Time Frame: Baseline up to 2 years ] [ Designated as safety issue: Yes ]
    Hypersensitivity reactions include Hypersensitivity, Drug hypersensitivity, Anaphylactic shock, Anaphylactic reaction, Anaphylactoid shock, Angioedema Anaphylactoid reaction, Blepharitis allergic, Dermatitis contact, Dermatitis allergic, Toxic skin eruption, Toxic epidermal necrolysis, Drug eruption, Erythema, Erythema multiforme, Tongue oedema, Pharyngeal oedema, Laryngeal oedema, Latex allergy, Paraesthesia oral, Paraesthesia mucosal, Urticaria, Stevens-Johnson syndrome, Rash, Skin reaction, Acute generalised exanthematous pustulosis, Drug rash with eosinphilia and systemic symptoms.


Enrollment: 501
Study Start Date: August 2006
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Observational study, no comparator
Observational study of patients with AMD treated with Macugen, no comparator
Drug: Macugen
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.

Detailed Description:

No comparator Patients with age-related macular degeneration

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with age-related macular degeneration

Criteria

Inclusion Criteria:

  • Neovascular AMD patients who are eligible for Macugen therapy based on the approved label

Exclusion Criteria:

  • Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460408

  Hide Study Locations
Locations
Belgium
Pfizer Investigational Site
Bruxelles, Belgium, 1200
Pfizer Investigational Site
Charleroi, Belgium, 6000
Pfizer Investigational Site
Ieper, Belgium, 8900
Pfizer Investigational Site
Lier, Belgium, 2500
Pfizer Investigational Site
Turnhout, Belgium, 2300
Cyprus
Pfizer Investigational Site
Lemesos, Cyprus, 1430
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic, 625 00
Pfizer Investigational Site
Hradec Kralove, Czech Republic, 500 05
Pfizer Investigational Site
Plzen, Czech Republic, 304 60
Pfizer Investigational Site
Praha 10, Czech Republic, 10034
Pfizer Investigational Site
Praha 2, Czech Republic, 128 08
Pfizer Investigational Site
Praha 6, Czech Republic, 169 02
Denmark
Pfizer Investigational Site
Soenderborg, Denmark, 6400
France
Pfizer Investigational Site
Argonay, France, 74370
Pfizer Investigational Site
Dijon, France, 21055
Pfizer Investigational Site
Grenoble, France, 38100
Pfizer Investigational Site
Le Golfe Juan, France, 06220
Pfizer Investigational Site
Marseille cedex 08, France, 13285
Pfizer Investigational Site
Rennes, France, 35033
Germany
Pfizer Investigational Site
Augsburg, Germany, 86156
Pfizer Investigational Site
Frankfurt, Germany, 60318
Pfizer Investigational Site
Karlsruhe, Germany, 76137
Pfizer Investigational Site
Konstanz, Germany, 78462
Pfizer Investigational Site
Ludwigshafen, Germany, 67063
Pfizer Investigational Site
Muenchen, Germany, 81675
Pfizer Investigational Site
Muenster, Germany, 48145
Pfizer Investigational Site
Weilheim, Germany, 82362
Greece
Pfizer Investigational Site
Heraklion, Crete, Greece, 71110
Pfizer Investigational Site
Nikea, Piraeus, Greece, 18454
Pfizer Investigational Site
Athens, Greece, 10672
Pfizer Investigational Site
Athens, Greece, 11526
Pfizer Investigational Site
Athens, Greece, 115 27
Pfizer Investigational Site
Heraklion, Greece, 71001
Pfizer Investigational Site
Ioannina, Greece, 45500
Pfizer Investigational Site
Kavala, Greece
Pfizer Investigational Site
Thessaloniki, Greece, 54636
Pfizer Investigational Site
Thessaloniki, Greece, 54642
Ireland
Pfizer Investigational Site
Waterford, Ireland
Italy
Pfizer Investigational Site
Arona, NO, Italy, 28041
Pfizer Investigational Site
Bologna, Italy, 40138
Pfizer Investigational Site
Cagliari, Italy, 09100
Pfizer Investigational Site
Monza, MI, Italy, 20052
Pfizer Investigational Site
Napoli, Italy, 80131
Pfizer Investigational Site
Pisa, Italy, 56124
Pfizer Investigational Site
Rieti, Italy, 02100
Pfizer Investigational Site
Siena, Italy, 53100
Poland
Pfizer Investigational Site
Bydgoszcz, Poland, 85 - 094
Pfizer Investigational Site
Szczecin, Poland, 70 - 111
Pfizer Investigational Site
Warszawa, Poland, 04-141
Slovakia
Pfizer Investigational Site
Banska Bystrica, Slovakia, 975 17
Pfizer Investigational Site
Bratislava, Slovakia, 826 06
Pfizer Investigational Site
Bratislava, Slovakia, 851 03
Pfizer Investigational Site
Kosice, Slovakia, 041 66
Pfizer Investigational Site
Presov, Slovakia, 081 81
Pfizer Investigational Site
Presov, Slovakia, 08001
Pfizer Investigational Site
Ruzomberok, Slovakia, 03426
Pfizer Investigational Site
Trencin, Slovakia, 911 71
Pfizer Investigational Site
Zilina, Slovakia, 012 07
Spain
Pfizer Investigational Site
Santiago de Compostela, A Coruña, Spain, 15706
Pfizer Investigational Site
Alcala de Henares, Madrid, Spain, 28805
Pfizer Investigational Site
Pamplona, Navarra, Spain, 31008
Pfizer Investigational Site
Madrid, Spain, 28040
Pfizer Investigational Site
Santa Cruz de Tenerife, Spain, 38010
Pfizer Investigational Site
Valencia, Spain, 46015
Pfizer Investigational Site
Valencia, Spain, 46014
Pfizer Investigational Site
Valladolid, Spain, 47010
Sweden
Pfizer Investigational Site
Stockholm, Sweden, 118 83
Pfizer Investigational Site
Västerås, Sweden, 721 89
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00460408     History of Changes
Other Study ID Numbers: A5751019
Study First Received: April 13, 2007
Results First Received: September 24, 2012
Last Updated: November 14, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Macular degeneration
Safety
Non-interventional
Non-randomized

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases

ClinicalTrials.gov processed this record on November 19, 2014